Navidoxine (Meclozine Hydrochloride)

Meclozine Hydrochloride, the active ingredient in Navidoxine, is an H1‑receptor antagonist presented as an oral dosage form for oral use. It is employed to alleviate symptoms of motion‑induced nausea, vertigo, and other vestibular‑related disturbances in adults and adolescents. By blocking peripheral histamine receptors and providing modest anticholinergic activity, it reduces vestibular stimulation that contributes to nausea and dizziness.

GNH USA supplies Navidoxine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Navidoxine, an H1‑receptor antagonist, is used in disorders where vestibular histamine activity contributes to symptoms.

- Motion sickness: reduces nausea, vomiting and dizziness caused by travel or movement. - Vertigo: alleviates spinning sensations associated with vestibular dysfunction. - Vestibular‑related nausea: diminishes nausea linked to inner‑ear disorders.

Navidoxine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to a parched sensation. - Blurred vision: temporary difficulty focusing. - Constipation: slowed intestinal transit. - Headache: mild to moderate head pain. - Fatigue: general lack of energy.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or angioedema. - Cardiac arrhythmia: irregular heartbeats, reported rarely. - Severe hypotension: marked drop in blood pressure. - Seizures: uncommon but possible in susceptible individuals. - Hepatic dysfunction: abnormal liver enzyme elevations. - Extrapyramidal symptoms: rare movement disorders.

Before prescribing Navidoxine, clinicians should consider several safety factors.

- Assess renal function: adjust use if severe impairment is present. - Evaluate hypersensitivity: avoid in patients with known allergy to meclozine or related antihistamines. - Caution in the elderly: increased risk of sedation and falls. - Limit alcohol consumption: may enhance central nervous system depression. - Pregnancy and lactation: use only when the potential benefit justifies the potential risk. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Navidoxine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, opioids): may potentiate sedation and respiratory depression. - Other anticholinergic agents (e.g., atropine, trihexyphenidyl): additive anticholinergic effects can cause severe dry mouth, constipation, or urinary retention. - Alcohol: synergistic drowsiness and impaired coordination.

Moderate Interactions (Monitor Closely):\n- Antihypertensive drugs: possible enhancement of blood‑pressure‑lowering effects. - Additional antihistamines: cumulative sedation. - CYP450 inhibitors (e.g., erythromycin, ketoconazole): may increase meclozine plasma concentrations. - Diuretics: potential for electrolyte imbalance when combined with anticholinergic effects. - Antidepressants (e.g., tricyclics): heightened anticholinergic burden.